News | Clinical Decision Support | November 21, 2018

Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018

Key collaborations will offer expanded capabilities to improve decision-making and patient care

Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018

November 21, 2018 — Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in medical imaging, at the 2018 annual meeting of the Radiological Society of North America (RSNA), Nov. 25-30 in Chicago.

Watson Imaging Patient Synopsis is a radiologist-trained artificial intelligence (AI) tool that extracts relevant patient information summarized into tailored, specific and concise single-view reports to better inform diagnostic decisions. Guerbet will demonstrate Patient Synopsis at RSNA 2018 alongside its Digital Services offerings.

Guerbet, an IBM Business Partner, and IBM are finalizing the terms by which Guerbet will become the first reseller of Patient Synopsis. This planned reseller relationship is in addition to IBM and Guerbet's ongoing efforts to co-develop and distribute new clinical decision support solutions. Earlier this year, Guerbet signed a joint development agreement with IBM Watson Health to develop an AI software solution supporting liver cancer diagnostics and care.

Guerbet's Contrast&Care is also part of Guerbet's Digital Services offerings. It enables radiology departments to collect, archive, examine and share contrast injection data directly with Guerbet's injectors, advancing data transfer and accuracy in dosing to help radiologists best serve patients. Likewise, at RSNA, Guerbet will display Imalogix, a cloud-based performance management and dose monitoring solution already available in the USA market.

For more information: www.guerbet-us.com

Related Content

Konica Minolta and Shimadzu to Co-market Dynamic Digital Radiography in the U.S.
News | Digital Radiography (DR) | July 23, 2019
Konica Minolta Healthcare Americas Inc. along with Shimadzu Medical Systems USA announced a collaborative agreement to...
John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019

John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019. Photo by Greg Freiherr

Feature | Radiology Business | July 22, 2019 | By Greg Freiherr
Efforts to reform healthcare are booming, b
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
Johns Hopkins Named Qualified Provider-led Entity to Develop Criteria for Diagnostic Imaging
News | Clinical Decision Support | July 18, 2019
On June 30, 2019, the Centers for Medicare & Medicaid Services (CMS) announced the Johns Hopkins University School...
Anatomage Releases Anatomage Cloud Platform
News | Remote Viewing Systems | July 16, 2019
Anatomage Inc. released an update to the Anatomage Cloud platform that allows medical and dental professionals to...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...